Clinical applications of genetic technologies to cancer care

Cancer Nursing

Volumn 20, Issue 5, 1997, Pages 359-377

  Peters, June ^a   Dimond, Eileen ^a   Jenkins, Jean ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOPROPHYLAXIS; DISEASE PREDISPOSITION; GENE THERAPY; GENETICS; GENOTYPE; HUMAN; NEOPLASM; NURSING; REVIEW; RISK FACTOR;

CHEMOPREVENTION; DISEASE SUSCEPTIBILITY; GENE THERAPY; GENOTYPE; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 0031242639     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-199710000-00007     Document Type: Article

References (47)

1. Peters KF, Hadley DW. The human genome project. Cancer Nurs 1997:20:62-75.
2. Peters JA. Applications of Genetic technologies to cancer screening, prevention, diagnosis, prognosis and treatment. Semin Oncol Afo 1997:13:74-81.
3. Dimond E, Peters J, Jenkins J. The genetic basis of cancer. Cancer Nurs 1997; 20:213-26.
4. Varmus, H, Winberg RA. Genes and the biology of cancer. New York: Scientific American Library; 1993.
5. Middelton LA, Peters KF, Helmbold EA. Genes and inheritance. Genes and inheritance Cancer Nurs 1997;20:129-51.
6. Mathew CG. Screening for mutations in cancer predisposition genes. In: Eeles RA, Ponder BAJ, Easton DF, Horwich A, eds. Genetic predisposition to cancer. London, UK: Chapman & Hall Medical, 1996; 73-382.
7. National Cancer Institute Public Information Service. Cancer Genome Anatomy Project: Overview and First Year Implementation Plan. 1997; 1-800-4CANCER.
8. Lippman SM, Brenner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994;12:851-873.
9. Greenwald P, Kelloff G, Burch-Whitman C, Kramer B. Chemoprevention. CA: Cancer Clin 1995;45:31-49.
10. Swan DK, Ford B. Chemoprevention of cancer: review of the literature. One Nursing Forum 1997;24:719-27.
11. Nayfield S, Karp J, Ford L, Dorr F, Kramer BV. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991:83:1450-59.
12. Thompson I, Coltman C, Brawley O, Ryan A. Chemoprevention of prostate cancer. Semin Ural 1995;13:122-9.
13. Turner D, Berkel H. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. CanMedAssocJ 1993;149:595-602.
14. Vogel VG, Parker LS. Ethical issues of chemoprevention clinical trials. Cancer Control 1997;4:142-9.
15. Shaw GL, Mulshine JL. Biomarkers and histology of premalignant and malignant lesions. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer prevention and control. New York, NY: Marcel Dekker; 1995.
16. Caporaso N, Hayes RB, Dosemeci M, et al. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotypes. Cancer Res 1989;49:3675-9.
17. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
18. Weinstein IB, Santella RM, Perera F. Molecular biology and epidemiology of cancer. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer prevention and control. New York, NY: Marcel Dekker; 1995.
19. Ambrosone CB, Freudenheim JL, Graham S, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996;276:1494-1501.
20. Biesecker BB. Genetic testing for cancer susceptibility. Cancer Nurs 1997;20:285-96.
21. Burke W, Petersen G, Lynch P. The Cancer Genetics Studies Consortium, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: Hereditary nonpolyposis colon cancer. JAMA 1997a;277:915-9.
22. Burke W, Daly M, Garber J. The Cancer Genetics Studies Consortium, et al. Recommendations for follow-up care of individuals with inherited predisposition to cancer: BRCA1 and BRCA2. JAMA 1997b;277:997-1002.
23. Vasen HFA, van der Luijt RB, Slors JFM, et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996;348:433-5.
24. Decker RA. Long-term follow-up of a large North American kindred with multiple endocrine neoplasia type 2a. Surgery 1992;112:1066-1073.
25. MacArthur SD, Mecklin JP, Herrera L. Surgical management of familial cancer syndromes. In: Weber W, Mulvihill JJ, Narod SA. eds. Familial cancer management. Boca Raton, FL: CRC Press; 1996.
26. Lynch H. Invited editorial: Desmoid tumors: genotype-phenotype differences in familial adenomatous polyposis- A nosological dilemma. Am J Hum Genet 1996;59:1184-85.
27. Karsdorp N, Elderson A, Wittebol-Post D, et al. von Hippel-Lindau Disease: new strategies in early detection and treatment. Am J Med .1994;97:158-68.
28. Hartmann L, Jenkins R, Schaid D, Yang P. Prophylactic mastectomy: preliminary retrospective cohort analysis. Proc Am Assoc CancerRes 1997;38: 168.
29. Peters JA. Familial cancer risk part II: breast cancer risk counseling and genetic susceptibility testing. J OncolManagern 1994;3:14-22.
30. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst 1995;17:33-5.
31. Eastman P. NCI adopts new mammography screening guidelines for women. J Natl Cancer Inst 1997; 89:538-540.
32. National Institutes of Health Consensus Development Panel. NIH Consensus Development Conference Statement: Breast cancer screening for women ages 40-49, Jan 21-23, 1997. J Nail Cancer Inst 1997;89:1015-26.
33. Science News & Comment. The breast screening brawl. Science 997;275:1056-9.
34. Weber T. Science and medicine: clinical surveillance recommendations adopted forHNPCC. Lancet 1996;348:465.
35. Taylor AMR, Hemandez D, McConville CM, Woods CG, Stacey M, Biggs P, Byrd PJ, Areltt CF, Scott D. Malignant disease and variations in radiosensitivity in ataxia telangiectasia patients. In: Eeles RA, Ponder BAJ, Easton DF, Horwich A, eds. Genetic predisposition to cancer. London, UK: Chapman & Hall; 1996.
36. National Cancer Institute. RFA CA97-004 P101: Cancer Genetics Network.NIHGuide. May 23,1997;26:1-16.
37. Pfeifer JD, Wick MR. The pathological evaluation of neoplastic diseases. In: Murphy OP, Lawrence W Jr, Lenhard RE Jr, eds. American Cancer Society textbook of clinical oncology, 2nd ed. Atlanta, GA: ACS; 1995.
38. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
39. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. JNatl Cancer lust 1992;84:1109-14.
40. Glebov OK, McKenzie KE, White CA, et al. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 1994;54:3703-9.
41. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N EngU Med 1995;332:429-35.
42. Fields KK, Elfenbein GJ, Trudeau WL, et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14:1868-76.
43. Lippman ME. Biologic therapy of breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia, PA: Lippincott-Raven; 1996: 743-50.
44. Pegram M, Lipton A, Pietras R, et al. Phase II study of intravenous recombinant humanized anti-pi85 HER-2/neu monoclonal antibody (rHuMAb HER-2/new) plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 199514:106a. Abstract.
45. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? JNatl Cancer Inst 1997;89:21-39.
46. Blaese RM. Gene therapy for cancer and AIDS. Sei Am 1997;276: 91-5.
47. Lea DH. Gene therapy: current and future implications for oncology nursing practice. Semin OncolNurs 1997:13:115-22.